Kyle LaHucik

One of the nation’s premier cancer institutions is looking at a hefty second batch of capital to support future drugs in the field.

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it unveiled with a $400 million-plus fund ...

Eli Lilly is deepening its presence in the non-opioid pain field by buying California biotech SiteOne Therapeutics, which is in a similar arena as the recent landmark approval for Vertex's pain drug.

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with the Murdoch Children's Research Institute in Australia. The California biotech, which has ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the exclusive ex-China license to the biotech's PD-1xVEGF bispecific.

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said Monday morning. The biotech plans to report results ...

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for biotech IPOs since 2022.

Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so far this year.

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with potential drug approval in 2028.

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.

Insilico Medicine files third HKEX IPO attempt, as biotech develops rentosertib for IPF and other drugs with AI-driven discovery platform

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new drug development outfits, medical technology startups and adjacent computational software ...

A Singapore-based startup raised a $45 million Series B to start testing a gene therapy in humans next year for a genetic heart muscle disorder, signaling that the AAV-based gene ...

PAQ Therapeutics has taken a new direction. The startup shifted its protein degradation approach to the more common PROTAC lane, pivoted to cancer, hired a chief medical officer from Frontier ...

Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 million, per a new regulatory filing.

Eli Lilly partners with Creyon Bio in $13M upfront deal, potential $1B+ milestone payments. CEO Serge Messerlian leads startup developing RNA-targeted medicines using aptamer technology.

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership team with industry veterans.

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A. The startup, named Grove Biopharma, weathered the pandemic and, after ...

Zealand Pharma hires Eli Lilly veteran Utpal Singh as CSO to advance peptide platform, following Roche obesity drug deal and partnerships with Boehringer Ingelheim.